The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL

OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
an isouch a facility			
CIK (Filer ID Number)	Previous Names	None	Entity Type
0001404281	Novus Therape	eutics, Inc.	X Corporation
Name of Issuer	Tokai Pharmac		Limited Partnership
Eledon Pharmaceuticals, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Org	ganization		General Partnership
DELAWARE			
Year of Incorporation/Organizat	ion		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spe	cify Year)		
Yet to Be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Eledon Pharmaceuticals, Inc.			
Street Address 1		Street Address 2	
19900 MACARTHUR BLVD.		SUITE 550	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
IRVINE	CALIFORNIA	92612	949-238-8090
3. Related Persons			
Last Name	First Name		Middle Name
Gros	David-Alexandre		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Co	untry	ZIP/PostalCode
Irvine	CALIFORNIA		92612
Relationship: X Executive Office	cer X Director Promoter		
Clarification of Response (if Nec	essary):		
Last Name	First Name		Middle Name
Little	Paul		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Co	untry	ZIP/PostalCode
Irvine	CALIFORNIA		92612
Relationship: $\overline{\mathbf{X}}$ Executive Office	cer Director Promoter		
Clarification of Response (if Nec	essary):		
Last Name	First Name		Middle Name
Perrin	Steven		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Co	untry	ZIP/PostalCode
Irvine	CALIFORNIA		92612
Relationship: X Executive Office	cer X Director Promoter		
· <u> </u>			

Clarification of Response (if Neces	sary):		
Last Name	First Name	Middle Name	
Smith	Bryan		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
Relationship: X Executive Officer		3 3 33	
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Katkin	Keith	Madio Namo	
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
_		32012	
· <u> </u>	X Director Promoter		
Clarification of Response (if Neces	Sary).		
Last Name	First Name	Middle Name	
Lyons	Gary		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Hillson	Jan	Madio Namo	
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
	X Director Promoter	32012	
Clarification of Response (if Neces			
Last Name	First Name	Middle Name	
McBride	John		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
Relationship: Executive Officer		32012	
Clarification of Response (if Neces			
Ciamication of Response (if Neces	Sary).		
Last Name	First Name	Middle Name	
Lee	June		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	

Ogier	Walter		
Street Address 1	Street Address 2		
19900 MacArthur Boulevard	Suite 550		
City	State/Province/Country	ZIP/PostalCode	
Irvine	CALIFORNIA	92612	
Relationship: Executive Officer X Direct			
Relationship. Executive Officer Direct	Ctol Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	X Biotechnology		
Commercial Banking	Health Insurance	Restaurants	
Insurance		Technology	
Investing	Hospitals & Physicians	Computers	
Investment Banking	Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	Travel	
an investment company under	Real Estate		
the Investment Company		Airlines & Airports	
Act of 1940?	Commercial	Lodging & Conventions	
∐Yes ∐No	Construction	Tourism & Travel Services	
Other Banking & Financial Services	REITS & Finance	Other Travel	
Business Services	Residential		
Energy		Other	
Coal Mining	Other Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset Va	alue Range	
X No Revenues	No Aggregate Net A	_	
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,00	0.000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,0		
\$25,000,001 -	H		
\$100,000,000	\$50,000,001 - \$100,	000,000	
Over \$100,000,000	Over \$100,000,000		
Decline to Disclose	Decline to Disclose		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion(s	s) Claimed (select all that apply)		
	Investment Comp	any Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)	<u> </u>		
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)	
X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)			
	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

7. Type of Filing		
X New Notice Date of First Sale 2023-05-05 First Sale Ye Amendment	t to Occur	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
 X Equity Debt X Option, Warrant or Other Right to Acquire Another Security X Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security 	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Tother Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combi merger, acquisition or exchange offer?	ination transaction, such as a Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 US	GD .	
12. Sales Compensation		
Recipient	Recipient CRD Number None	
SVB Securities LLC	39011	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None	
None	None	
Street Address 1	Street Address 2	
53 State Street City	40th Floor State/Province/Country	ZIP/Postal Code
Boston	MASSACHUSETTS	02109
State(s) of Solicitation (select all that apply) Check "All States" or check individual States $\overline{\mathbf{X}}$ All States	X Foreign/non-US	
Recipient	Recipient CRD Number None	
Noble Capital Markets, Inc.	15768	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None	
None	None	
Street Address 1	Street Address 2	
150 East Palmetto Park Road City	Suite 110 State/Province/Country	ZIP/Postal Code
Boca Raton	FLORIDA	33432
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	X Foreign/non-US	
CALIFORNIA		
DELAWARE		
FLORIDA		
IDAHO		
NEVADA		
NEW HAMPSHIRE NEW JERSEY		
NEW YORK		
TEXAS		
13. Offering and Sales Amounts		

Total Offering Amount	USD or X Indefinite	
Total Amount Sold	\$35,000,000 USD	
Total Remaining to be Sold	d USD or X Indefinite	
Clarification of Response (i	f Necessary):	
	in initial closing; plus \$45M assuming exercise of all common warrants issued in initial closing; and \$46.7M are in 2nd and 3rd closings, upon the satisfaction of specified conditions.	and \$58.3M upon
4. Investors		
	he offering have been or may be sold to persons who do not qualify as accredited investors, and uch non-accredited investors who already have invested in the offering.	
	r securities in the offering have been or may be sold to persons who do not qualify as accredited cal number of investors who already have invested in the offering:	38
5. Sales Commissions &	Finder's Fees Expenses	
Provide separately the amount of the land the land check the land check the land check the land the la	ounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not box next to the amount.	t known, provide
Sales Comr	missions \$1,227,961 USD Estimate	
Finde	ers' Fees \$0 USD Estimate	
Clarification of Response (i	f Necessary):	
6. Use of Proceeds		
	gross proceeds of the offering that has been or is proposed to be used for payments to any of the procers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estime.	
	\$0 USD Estimate	

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Eledon Pharmaceuticals, Inc.	/s/ Paul Little	Paul Little	Chief Financial Officer	2023-05-19

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.